GlassScriptPhysician profile
Benjamin Seunghoon Lee
NPI 1730156746
$3,848.70
in general payments reported to CMS, 2019-2025
32 companies · $18.85 in 2025
The $18.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,155 · 2020: $446 · 2021: $574 · 2022: $857 · 2023: $694 · 2024: $103 · 2025: $18.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.31 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $432.29 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $369.64 | 2019-2023 | Breztri, Farxiga |
| Amgen INC. | $340.83 | 2019-2024 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.42 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $236.60 | 2019-2023 | |
| Glaxosmithkline, LLC. | $208.17 | 2019-2023 | Shingrix |
| Sunovion Pharmaceuticals INC. | $186.96 | 2019-2022 | |
| Lilly USA, LLC | $171.77 | 2020-2023 | Mounjaro, Trulicity, Jardiance |
| Scilex Pharmaceuticals INC. | $152.59 | 2019-2024 | Ztlido |
| Novo Nordisk INC | $145.29 | 2019-2022 | |
| Astellas Pharma US INC | $134.94 | 2019-2022 | |
| Gilead Sciences, INC. | $133.35 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $124.55 | 2023-2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $122.83 | 2019 | |
| Abbvie INC. | $113.98 | 2019-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $83.09 | 2019-2022 | |
| Eisai INC. | $79.91 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $72.33 | 2020-2022 | |
| Medtronic USA, INC. | $59.72 | 2019 | |
| Pfizer INC. | $51.04 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $49.50 | 2019-2021 | |
| Abbott Laboratories | $42.96 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $41.08 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.16 | 2019-2022 | |
| Biogen, INC. | $32.74 | 2021-2022 | |
| Horizon Therapeutics Plc | $28.49 | 2022-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $24.38 | 2019 | |
| Grifols USA, LLC | $21.65 | 2019 | |
| Ardelyx, INC. | $21.13 | 2023 | Ibsrela |
| Ibsa Pharma INC. | $21.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.07 | 2022 | |
| Radius Health, INC. | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.